Evaluation of the main prenatal routine exams (Part 1);Avaliação dos exames de rotina no pré-natal (Parte 1)

Revista Brasileira de Ginecologia e Obstetricia

Volumn 31, Issue 3, 2009, Pages

  Amorim, Melania Maria Ramos ^a,b   Melo, Adriana Suely de Oliveira ^a,b  

^a INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

^b Instituto de Pesquisa Professor Joaquim Amorim Neto   (Brazil)

Author keywords

Evidence based medicine; Maternal welfare; Perinatal care; Pregnancy; Prenatal care; Quality of health care

Indexed keywords

EID: 67749099352     PISSN: 01007203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Associação Médica Brasileira. Conselho Federal de Medicina. Projeto Diretrizes: introdução [Internet]. São Paulo; 2008 [citado 2008 Abr 6]. Disponível em: http://www.projetodiretrizes.org.br/projeto_diretrizes/texto_introdutorio.pdf
2. World Health Organization (WHO). Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva: WHO; 2001.
3. Reveiz L, Gyte GM, Cuervo LG. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2008;(4):CD003094.
4. Ministério da Saúde. Pré-natal e puerpério: atenção qualificada e humanizada. Brasília, DF: Secretaria de Atenção à Saúde/ Departamento de Ações Programáticas Estratégicas; 2005.
5. U.S. Preventive Services Task Force (USPSTF). Screening for iron deficiency anemia: including iron supplementation for children and pregnant women. Rockville: Agency for Healthcare Research and Quality (AHRQ); 2006.
6. Doroshenko A, Sherrad J, Pollard AJ. Syphilis in pregnancy and the neonatal period. Int J STD AIDS. 2006;17(4):221-7.
7. Rothschild BM. History of syphilis. Clin Infect Dis. 2005;40(10):1454-63.
8. Saloojee H, Velaphi S, Goga Y, Afadapa N, Steen R, Lincetto O. The prevention and management of congenital syphilis: An overview and recommendations. Bull World Health Organ. 2004;82(6):421-30.
9. Rodrigues CS, Guimarães MDC. Positividade para sífilis em puérperas: ainda um desafio para o Brasil. Rev Panam Salud Publica. 2004;16(3):168-75.
10. Lumbiganon P, Piaggio G, Villar J, Pinol A, Bakketeig L, Bergsjo P, et al. The epidemiology of syphilis in pregnancy. Int J STD AIDS. 2002;13(7):486-94.
11. U.S. Preventive Services Task Force (USPSTF). Screening for syphilis infection: recommendation statement. Rockville: Agency for Healthcare Research and Quality (AHRQ); 2004.4
12. Buffolano W. Congenital toxoplasmosis: the state of the art. Parassitologia. 2008;50(1-2):37-43.
13. Figueiró-Filho EA, Senefonte FR, Lopes AH, Morais OO, Souza Júnior VG, Maia TL, et al. Freqüência das infecções pelo HIV-1, rubéola, sífilis, toxoplasmose, citomegalovírus, herpes simples, hepatite B, hepatite C, doença de Chagas e HTLV I/II em gestantes, do Estado de Mato Grosso do Sul. Rev Soc Bras Med Trop. 2007;40(2):181-7.
14. Porto AMF, Amorim MMR, Coelho ICN, Santos LC. Perfil sorológico para toxoplasmose em gestantes atendidas em maternidade. Rev Assoc Med Bras. 2008;54(3):242-8.
15. Peyron F, Wallon M, Liou C, Garner P. Treatments for toxoplasmosis in pregnancy. Cochrane Database Syst Rev. 2008;(4):CD001684.
16. SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet. 2007;369(9556):115-22. Review.
17. Wallon M, Liou C, Garner P, Peyron F. Congenital toxoplasmosis: systematic review of evidence of efficacy of treatment in pregnancy. BMJ. 1999;318(7197):1511-4.
18. Lazzarotto T, Gabrielli L, Lanari M, Guerra B, Bellucci T, Sassi M, et al. Congenital cytomegalovirus infection: recent advances in the diagnosis of maternal infection. Hum Immunol. 2004;65(5):410-5.
19. Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol. 2007;17(4):253-76.
20. Munro ND, Sheppard S, Smithells RW, Holzel H, Jones G. Temporal relations between maternal rubella and congenital defects. Lancet. 1987;2(8552):201-4.
21. Muller CP, Kremer JR, Best JM, Dourado I, Triki H, Reef S, WHO Steering Committee for Measles and Rubella. Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine. 2007;25(1):1-9.
22. Giraudon I, Forde J, Maguire H, Arnold J, Permalloo N. Antenatal screening and prevalence of infection: surveillance in London, 2000-2007. Euro Surveill. 2009;14(9):8-12.
23. Bacq Y. Hepatitis B and pregnancy. Gastroenterol Clin Biol. 2008;32(1 Pt 2):S12-9.
24. Knorr B, Maul H, Schnitzler P. Prevalence of hepatitis B virus infection among women at reproductive age at a German university hospital. J Clin Virol. 2008;42(4):422-4.
25. Arraes LC, Sampaio AS, Barreto S, Guilherme MSA, Lorenzato F. Prevalência de hepatite B em parturientes e perfil sorológico perinatal. Rev Bras Ginecol Obstet. 2003;25(8):571-6.
26. Armstrong W, Calabrese L, Taege AJ. HIV update 2005: origins, issues, prospects, and complications. Cleve Clin J Med. 2005;72(1):73-8.
27. Peters VB, Liu KL, Robinson LG, Dominguez KL, Abrams EJ, Gill BS, et al. Trends in perinatal HIV prevention in New York City, 1994-2003. Am J Public Health. 2008;98(10):1857-64.
28. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007;(1):CD003510. Update of: Cochrane Database Syst Rev. 2002;(2):CD003510.
29. Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev. 2008;(4):CD005479.
30. Jourdain G, Mary JY, Coeur SL, Ngo-Giang-Huong N, Yuthavisuthi P, Limtrakul A, Traisathit P, McIntosh K, Lallemant M; Perinatal HIV Prevention Trial Group, Thailand. Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. J Infect Dis. 2007;196(1):1629-36.
31. Rates of mother-to-child transmission of HIV-1 in Africa, America and Europe: results of 13 perinatal studies. The Working Group on Mother-To-Child Transmission of HIV. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(5):506-10.
32. Elective caesarean-section versus vaginal delivery in prevention of vertical transmission: a randomised clinical trial. The European Mode of Delivery Collaboration. Lancet. 1999;353(9158):1035-9.
33. Andriole VT, Patterson TF. Epidemiology, natural history, and management of urinary tract infections in pregnancy. Med Clin North Am. 1991;75(2):359-73.
34. McIsaac W, Carroll JC, Biringer A, Bernstein P, Lyons E, Low DE, et al. Screening for asymptomatic bacteriuria in pregnancy. J Obstet Gynaecol Can. 2005;27(1):20-4.
35. U.S. Preventive Services Task Force. Screening for asymptomatic bacteriuria in adults: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2008;149(1):43-7.
36. Smaill F, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev. 2007;(2):CD000490. Update of: Cochrane Database Syst Rev. 2001;(2):CD000490.
37. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191(1):105-13.
38. Hunter MI, Monk BJ, Tewari KS. Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease. Am J Obstet Gynecol. 2008;199(1):3-9.
39. Colbourn T, Asseburg C, Bojke L, Philips Z, Claxton K, Ades AE, et al. Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses. Health Technol Assess. 2007;11(29):1-226, iii.
40. Smaill F. Intrapartum antibiotics for group B streptococcal colonization. Cochrane Database Syst Rev. 2008;(4):CD000115.
41. Centers for Disease Control and Prevention (CDC). Disparities in universal prenatal screening for group B streptococcus-- North Carolina, 2002-2003. MMWR Morb Mortal Wkly Rep. 2005;54(28):700-3.
42. Davies HD, Miller MA, Faro S, Gregson D, Kehl SC, Jordan JA. Multicenter study of a rapid molecular-based assay for the diagnosis of group B Streptococcus colonization in pregnant women. Clin Infect Dis. 2004;39(8):1129-35.
43. Subair O, Wagner P, Omojole F, Morgan H. Group B streptococcus disease in neonates: to screen or not to screen? J Obstet Gynaecol. 2005;25(5):462-4.
44. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: WHO; 2001.
45. Barcelos MRB, Vargas PRM, Baroni C, Miranda AE. Infecções genitais em mulheres atendidas em Unidade Básica de Saúde: prevalência e fatores de risco. Rev Bras Ginecol Obstet. 2008;30(7):349-54.
46. Andrews WW, Goldenberg RL, Mercer B, Iams J, Meis P, Moawad A, et al. The Preterm Prediction Study: association of second- trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. Am J Obstet Gynecol. 2000;183(3): 662-8.
47. Blas MM, Canchihuaman FA, Alva IE, Hawes SE. Pregnancy outcomes in women infected with Chlamydia trachomatis: a population-based cohort study in Washington State. Sex Transm Infect. 2007;83(4):314-8.
48. U.S. Preventive Services Task Force. Screening for chlamydial infection: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;147(2):128-34.
49. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51(RR-6):1-78.